Skip to main content
SpringerLink
Log in

Hormonal Manipulation of Prostate Cancer

  • Chapter
Endocrine Oncology

Part of the book series: Contemporary Endocrinology ((COE))

  • 142 Accesses

Abstract

Prostate cancer (PC) is a hormonally responsive disease. Testosterone (T) is required for the development of early PC and the disease retains this dependence through most of its natural history. The reliance of most PC cells on T offers an opportunity for clinical intervention in patients with this disease. That is, if the level of T can be diminished, the prostate cancer should respond with a reduction in size, which should bring about an improvement in clinical symptoms. Hormonal manipulations of PC all share one ultimate goal: Decrease the physiologic effect of T.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Huggins C, Hodges C. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphotases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.

    CAS  Google Scholar 

  2. Huggins C, Stevens RE, Hodges C. Studies on prostatic cancer. II: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223.

    Article  CAS  Google Scholar 

  3. Huggins C, Scott WW, Hodges CV. Studies on prostatic cancer III. The effects of fever, of deoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 1941; 46: 997–1001.

    CAS  Google Scholar 

  4. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991–1998.

    Article  PubMed  CAS  Google Scholar 

  5. Kent JR, Bischoff AJ, Arduino LJ, et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 1973; 109: 858–862.

    PubMed  CAS  Google Scholar 

  6. Beck PH, McAninch JW, Goebel JL, Stutzman RE. Plasma testosterone in patients receiving diethylstilbestrol. Urology 1978; 11: 157–160.

    Article  PubMed  CAS  Google Scholar 

  7. Baker HW, Burger HG, DeKretser DM, Hudson B, Straffon WG. Effects of synthetic oral oestrogens in normal men and patients with prostatic carcinoma: lack of gonadotrophin suppression by chlorotrianisene. Clin Endocrinol 1973; 2: 297–301.

    Article  CAS  Google Scholar 

  8. The Veteran’s Administration Cooperative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967; 98: 516–522.

    Google Scholar 

  9. Byar DP. Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973; 32: 1126–1130.

    Article  PubMed  CAS  Google Scholar 

  10. Bailar III JC, Byar DP. Veterans Administration Cooperative Urological Research Group. Estrogen treatment for cancer of the prostate: early results with three doses of diethylstilbestrol and placebo. Cancer 1970; 26: 257–261.

    Google Scholar 

  11. Byar DP, Corle DK. Veterans Administration Cooperative Urological Research Group randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology 1981; 17 (Suppl): 7–11.

    Google Scholar 

  12. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veteran’s Administration Cooperative Urological Research Group Studies. Natl Cancer Inst Monogr 1988; 7: 165–170.

    Google Scholar 

  13. Galbraith SM, Duchesne GM. Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur J Cancer 1997; 33: 545–554.

    Article  PubMed  CAS  Google Scholar 

  14. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281–1286.

    Google Scholar 

  15. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33 (Suppl 5): 45–52.

    Article  PubMed  CAS  Google Scholar 

  16. Waymont B, Lynch TH, Dunn JA, et al. Phase III randomised study of Zoladex versus stilbestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 614–620.

    Article  PubMed  CAS  Google Scholar 

  17. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220–226.

    Article  PubMed  CAS  Google Scholar 

  18. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–508.

    Article  PubMed  CAS  Google Scholar 

  19. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL. Orchiectomy versus long acting D-Trp-6LHRH in advanced prostate cancer. Br J Urol 1987; 59: 248–254.

    Article  PubMed  CAS  Google Scholar 

  20. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbesterol. J Clin Oncol 1996; 14: 2250–2257.

    PubMed  CAS  Google Scholar 

  21. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47 (Suppl 1A): 38–43.

    Article  PubMed  CAS  Google Scholar 

  22. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of `Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447–456.

    Article  PubMed  CAS  Google Scholar 

  23. Geller J, de la Vega DJ, Albert JD, Nachtsheim DA. Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab 1984; 58: 36–40.

    Article  PubMed  CAS  Google Scholar 

  24. Brendler H. Adrenalectomy and hypophysectomy for prostatic cancer. Urology 1973; 2: 99–102.

    Article  PubMed  CAS  Google Scholar 

  25. Huggins C, Scot WW. Bilateral adrenalectomy in prostatic cancer. Ann Surg 1945; 122: 1031–1041.

    Article  Google Scholar 

  26. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579–594.

    Article  PubMed  CAS  Google Scholar 

  27. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–424.

    Article  PubMed  CAS  Google Scholar 

  28. Denis L, Whelan P, Carneiro de Moura JL, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993; 42: 119–130.

    Article  PubMed  CAS  Google Scholar 

  29. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77–83.

    PubMed  CAS  Google Scholar 

  30. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72 (Suppl): 3888–3895.

    Google Scholar 

  31. Caubet J, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71–78.

    Article  PubMed  CAS  Google Scholar 

  32. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265–269.

    Google Scholar 

  33. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral Orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036–1042.

    Article  PubMed  CAS  Google Scholar 

  34. Kuhn J, Billebaud T, Navrath H, et al. Prevention of the transient adverse effects of a gonadatropinreleasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an anti-androgen (nilutamide). N Engl J Med 1989; 321: 413–418.

    Article  PubMed  CAS  Google Scholar 

  35. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-independent tumors. Cancer 1993; 71: 2782–2790.

    Article  PubMed  CAS  Google Scholar 

  36. Bruchovsky N, Rennie PS, Goldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275–2282.

    PubMed  CAS  Google Scholar 

  37. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996; 30 (Suppl 1): 22–25.

    PubMed  Google Scholar 

  38. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839–844.

    Article  PubMed  CAS  Google Scholar 

  39. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800–804.

    Article  PubMed  CAS  Google Scholar 

  40. Horwich A, Huddart RA, Gadd J, et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96–99.

    Article  PubMed  CAS  Google Scholar 

  41. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51: 137–144.

    Article  PubMed  CAS  Google Scholar 

  42. Presti JC, Fair WR, Andriole G, et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992; 148: 1201–1204.

    PubMed  Google Scholar 

  43. Brufsky A, Fontaine-Roth P, Berlane K, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913–920.

    Article  PubMed  CAS  Google Scholar 

  44. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48: 901–905.

    Article  PubMed  CAS  Google Scholar 

  45. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995; 154: 1642–1646.

    Article  PubMed  CAS  Google Scholar 

  46. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996; 78: 907–910.

    Article  PubMed  CAS  Google Scholar 

  47. Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol 1993; 24 (Suppl 2): 106–112.

    PubMed  Google Scholar 

  48. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride induced gynecomastia. Urology 1997; 50: 929–933.

    Article  PubMed  CAS  Google Scholar 

  49. Vest SA, Frazier TR Survival following castration for prostatic cancer. J Urol 1946; 56: 97–102.

    PubMed  CAS  Google Scholar 

  50. Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma: clinical and statistical survey of 1,818 cases. J Am Med Assoc 1950; 143: 1317–1320.

    Article  PubMed  CAS  Google Scholar 

  51. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128: 335–340.

    PubMed  CAS  Google Scholar 

  52. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostatic cancer. Cancer 1980; 45: 1929–1936.

    PubMed  CAS  Google Scholar 

  53. Kramolowsky EV. The value of testosterone deprivation in stage DI carcinoma of the prostate. J Urol 1988; 139: 1242–1244.

    PubMed  CAS  Google Scholar 

  54. van Aubel OGJM, Hoekstra WJ, Schroder FH. Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 1985; 134: 292–294.

    PubMed  Google Scholar 

  55. Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989; 33 (Suppl 5): 27–36.

    Article  PubMed  CAS  Google Scholar 

  56. Myers RP, Zincke H, Fleming TR, Farrow GM, Furlow WL, Utz DC. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. J Urol 1983; 130: 99–101.

    PubMed  CAS  Google Scholar 

  57. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–246.

    Article  Google Scholar 

  58. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607–609.

    PubMed  CAS  Google Scholar 

  59. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566–1572.

    PubMed  CAS  Google Scholar 

  60. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98: 412–415.

    Article  PubMed  CAS  Google Scholar 

  61. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76: 1428–1434.

    Article  PubMed  CAS  Google Scholar 

  62. Small EJ, Carroll PR. Prostate-specific antigen decline after Casodex withdrawal: evidence for an anti-androgen withdrawal syndrome. Urology 1994; 43: 408–410.

    Article  PubMed  CAS  Google Scholar 

  63. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megesterol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946–1949.

    Article  PubMed  CAS  Google Scholar 

  64. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995; 153: 1944, 1945.

    Google Scholar 

  65. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995; 13: 2208–2213.

    PubMed  CAS  Google Scholar 

  66. Drago JR, Santen RJ, Lipton A, et al. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984; 53: 1447–1450.

    Article  PubMed  CAS  Google Scholar 

  67. Elomaa I, Taube T, Blomqvist C, Rissanen P, Rannikko S, Alfthan O. Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy. Eur Urol 1988; 14: 104–106.

    PubMed  CAS  Google Scholar 

  68. Chang AYC, Bennett JM, Pandya KJ, Asbury R, McCune C. A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol 1989; 12: 358–360.

    Article  PubMed  CAS  Google Scholar 

  69. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of “hormone refractory” prostate cancer. J Natl Cancer Inst 1994; 86: 222–227.

    Article  PubMed  CAS  Google Scholar 

  70. Dupont A, Gomez J, Cusan L, Koutsiliers M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908–913.

    PubMed  CAS  Google Scholar 

  71. Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effects on prostate carcinoma cells. J Urol 1989; 141: 190–191.

    PubMed  CAS  Google Scholar 

  72. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1989; 7: 1093–1098.

    PubMed  CAS  Google Scholar 

  73. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204–1207.

    Article  PubMed  CAS  Google Scholar 

  74. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80: 1755–1759.

    Article  PubMed  CAS  Google Scholar 

  75. Kolvenberg GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998; 34: 61–72.

    Article  Google Scholar 

  76. Furr BJA. Casodex: preclinical studies. Eur Urol 1990; 18 (Suppl 3): 22–25.

    PubMed  Google Scholar 

  77. Figg WD, McNall NA, Reed E, et al. The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP. Oncol Rep 1995; 2: 295–298.

    PubMed  CAS  Google Scholar 

  78. Wilding G, Chen M, Gelman EP. Aberrant response in vitro of hormone responsive prostate cancer cells to anti-androgens. Prostate 1989; 14: 103–115.

    Article  PubMed  CAS  Google Scholar 

  79. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928–2938.

    PubMed  CAS  Google Scholar 

  80. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. J Clin Oncol 1998; 16: 1835–1843.

    PubMed  CAS  Google Scholar 

  81. Joyce R, Fenton MA, Rose P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149–153.

    Article  PubMed  CAS  Google Scholar 

  82. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88: 908–917.

    Article  PubMed  CAS  Google Scholar 

  83. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. Phase II trial of oral diethylstilbesterol as a second line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257–260.

    Article  PubMed  CAS  Google Scholar 

  84. Hanks GE, Corn BW, Lee WR, Hunt M, Hanlon A, Schultheiss TE. External beam irradiation of prostate cancer: conformal treatment techniques and outcomes for the 1990s. Cancer 1995; 75: 1972–1977.

    Article  Google Scholar 

  85. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994; 28: 7–16.

    Article  PubMed  CAS  Google Scholar 

  86. Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy or combined treatment: a Medical Research Council study. Br J Urol 1992; 70: 304–309.

    PubMed  CAS  Google Scholar 

  87. Pilepich MV, Suase WT, Shipley WU, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616–623.

    Article  PubMed  CAS  Google Scholar 

  88. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85–31. J Clin Oncol 1997; 15: 1013–1021.

    PubMed  CAS  Google Scholar 

  89. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300.

    Article  PubMed  CAS  Google Scholar 

  90. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical prostatectomy: results at ten years. J Urol 1994; 152: 1831–1836.

    PubMed  CAS  Google Scholar 

  91. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J Urol 1995; 154: 424–428.

    Article  PubMed  CAS  Google Scholar 

  92. Van Poppel H, de Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995; 154: 429–434.

    Article  PubMed  Google Scholar 

  93. Labrie F, Cusan L, Gomez JL, et al. Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a leutinizing hormone-releasing hormone agonist. Urology 1994; 44: 29–37.

    Article  Google Scholar 

  94. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998; 160: 299–315.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jeffrey M. Kamradt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth J. Pienta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Michigan Cancer Center, Ann Arbor, MI, USA

    Stephen P. Ethier PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Kamradt, J.M., Pienta, K.J. (2000). Hormonal Manipulation of Prostate Cancer. In: Ethier, S.P. (eds) Endocrine Oncology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-223-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-223-4_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9700-7

  • Online ISBN: 978-1-59259-223-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation